Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00729703 · ClinicalTrials.gov registry record · Phase 4
Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications
A Phase 4 study of Tachycardia, sponsored by LivaNova.
- Completed
- Registry status
- Phase 4
- Development phase
- 462
- Enrollment target
- 20
- Study locations
NCT00729703 is a Phase 4 study of Tachycardia that has completed, run by LivaNova. The registered enrollment target is 462 participants, below the 841-participant average among 8 other Tachycardia trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT00729703, a Phase 4 study of Tachycardia, has completed, sponsored by LivaNova.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 462 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study evaluates the impact of a new pacing mode avoiding unnecessary ventricular stimulation in combination with advanced dual chamber detection with slow VT management on the clinical outcome for hospitalization and mortality and inadequate therapy in medically stable, ICD-indicated patients with impaired left ventricular function (LVEF ≤ 40%) who do not have pacing indications and no indication for Cardiac Resynchronization Therapy (CRT). It compares a new pacing mode avoiding ventricular stimulation when not needed combined with dual chamber detection with a pure ventricular back up pacing and single chamber detection criteria with pure ventricular back up pacing. Therapies are compared in a prospective, randomized, single-blinded, parallel trial with a 24-month randomized treatment period. Randomization follows a 1:1 ratio. ICD therapy is enabled for all patients throughout the study. All patients receive optimal drug therapy for arrhythmia and heart failure treatment.
Conditions Studied
Interventions
- DEVICE Ovatio DR 6550
- DEVICE OVATIO DR 6550
Study Locations (20)
Other
- Algemeen Ziekenhuis - Antwepen - Antwepen
- Kliniek Maria Middelares - Gent - Ghent
- Heart Center Virga Jesse Ziekenhuis - Hasselt - Hasselt
- CHUM Hotel-Dieu - Montreal
- Hôpital Sacré Coeur - Montreal
- Centre Hospitalier General - Aix-en-Provence
- CHU Le Haut L'Evêque - Bordeaux
- CHU Hôpital Michallon Grenoble - Grenoble
- Clinique De Parly II - Le Chesnay
- Clinique les sources - Le Mans
- CH ST Philibert - Lomme
- Hôpital St Joseph - Lyon
- Hopital Arnaud De Villeneuve - Montpellier
- CHU Nantes - Nantes
- Clinique Bizet - Paris
Georgia
- Piedmont Hospital Research Institute - Atlanta
- Atlanta Va Medical Center - Decatur
Louisiana
- Southern Medical Research, Llc - Mandeville
Ohio
- River City Cardiology - Jeffersonville
South Carolina
- Pee Dee Cardiology - Florence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2006-06 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00729703
The ClinicalTrials.gov registry entry for NCT00729703 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 841-participant average among 8 other Tachycardia trials with a reported enrollment target (45% lower). The listed sponsor is LivaNova, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Tachycardia appearing as the primary indexed condition, and to 2 interventions - of which Ovatio DR 6550 is the first listed.
NCT00729703 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Georgia, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00729703 about?
NCT00729703 is a clinical study titled "Optimal Anti-tachycardia Therapy in Implantable Cardioverter-defibrillator (ICD) Patients Without Pacing Indications". This study evaluates the impact of a new pacing mode avoiding unnecessary ventricular stimulation in combination with advanced dual chamber detection with slow VT management on the clinical outcome for hospitalization and mortality and inadequate therapy in medically stable, ICD-indicated patients w...
What is the current status of trial NCT00729703?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 462 participants. The study started on 2006-06. Estimated completion is 2013-10.
What conditions does trial NCT00729703 study?
This clinical trial studies the following conditions: Tachycardia.
What interventions are being tested in trial NCT00729703?
The interventions under investigation include: Ovatio DR 6550 (DEVICE), OVATIO DR 6550 (DEVICE).
Who is sponsoring clinical trial NCT00729703?
This trial is sponsored by LivaNova, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00729703 being conducted?
This trial has 20 study locations across Georgia, Louisiana, Ohio, South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
RIGHT: Rhythm ID Going Head-to-Head Trial
COMPLETED · Phase 4
-
TriVerity™ for Improved Management of Emergency Department (ED) Patients With Suspected Infections
RECRUITING · NA
-
Treatment of Orthostatic Intolerance
ACTIVE NOT RECRUITING · Phase 1
-
Detection and Classification of Cardiac Rhythm and Atrial Fibrillation Using a Finger-worn Ring
ACTIVE NOT RECRUITING
-
Enlighten Study: The EV-ICD Post Approval Registry
ACTIVE NOT RECRUITING
-
Pathophysiology of Orthostatic Intolerance
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.